To identify patient responders to cancer immunotherapy, Larimer and colleagues designed a molecular tracer starting from the cleavage sequence of murine granzyme B, modified it with NOTA chelator and radiolabelled with gallium-68 to produce a granzyme B specific PET agent (GZP) [90]. The gene discussed is GZMB; the disease is cancer.